How Important Is Eliquis For Bristol-Myers Squibb?

Bristol-Myers Squibb’s cardiovascular segment, which primarily consists of Eliquis, accounts for over 15% of the company’s value, according to our estimates. The company derives most of its value from oncology drugs, which we believe will also be the key growth drivers in the coming years

from Forbes Real Time https://www.forbes.com/sites/greatspeculations/2017/10/05/how-important-is-eliquis-for-bristol-myers-squibb/
via IFTTT